A detailed history of Davidson Trust CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Davidson Trust CO holds 11,525 shares of BMY stock, worth $457,081. This represents 0.37% of its overall portfolio holdings.

Number of Shares
11,525
Previous 10,962 5.14%
Holding current value
$457,081
Previous $562,000 11.21%
% of portfolio
0.37%
Previous 0.37%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$47.98 - $54.4 $27,012 - $30,627
563 Added 5.14%
11,525 $625,000
Q4 2023

Jan 31, 2024

BUY
$48.48 - $57.85 $9,889 - $11,801
204 Added 1.9%
10,962 $562,000
Q3 2023

Nov 08, 2023

BUY
$57.89 - $64.73 $7,930 - $8,868
137 Added 1.29%
10,758 $624,000
Q1 2023

Apr 24, 2023

BUY
$65.71 - $74.53 $137,333 - $155,767
2,090 Added 24.5%
10,621 $736,000
Q3 2022

Nov 07, 2022

SELL
$0.13 - $76.84 $8 - $4,994
-65 Reduced 0.76%
8,531 $606,000
Q2 2022

Jul 27, 2022

SELL
$72.62 - $79.98 $23,238 - $25,593
-320 Reduced 3.59%
8,596 $662,000
Q1 2022

May 12, 2022

SELL
$61.48 - $73.72 $22,132 - $26,539
-360 Reduced 3.88%
8,916 $651,000
Q4 2021

Jan 28, 2022

BUY
$53.63 - $62.52 $17,751 - $20,694
331 Added 3.7%
9,276 $578,000
Q3 2021

Nov 03, 2021

BUY
$59.17 - $69.31 $16,271 - $19,060
275 Added 3.17%
8,945 $529,000
Q2 2021

Aug 10, 2021

SELL
$61.91 - $67.42 $44,389 - $48,340
-717 Reduced 7.64%
8,670 $579,000
Q1 2021

May 07, 2021

BUY
$59.34 - $66.74 $3,560 - $4,004
60 Added 0.64%
9,387 $592,000
Q3 2020

Nov 02, 2020

SELL
$57.43 - $63.64 $4,020 - $4,454
-70 Reduced 0.74%
9,327 $561,000
Q1 2020

May 06, 2020

BUY
$46.4 - $67.43 $28,164 - $40,930
607 Added 6.91%
9,397 $523,000
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $432,555 - $564,230
8,790 New
8,790 $564,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $84.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Davidson Trust CO Portfolio

Follow Davidson Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Davidson Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Davidson Trust CO with notifications on news.